Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
May 21 2024 - 12:15PM
Business Wire
Incyte (Nasdaq:INCY) today announced the expansion of its
presence in Delaware with the acquisition of two buildings at 1100
North King Street and 1100 North French Street in downtown
Wilmington. This acquisition marks Incyte’s fourth expansion in
Delaware since establishing operations in Alapocas in 2014. The new
buildings will allow the Company’s U.S.-based teams to be located
together as they continue to deliver on their commitment to finding
innovative solutions for patients with critical unmet medical
needs.
“We are thrilled to reinforce our ongoing commitment to Delaware
by expanding our presence here. The acquisition of these new
buildings will allow our U.S. commercial and medical affairs teams
to return to Delaware, enable closer collaboration between our
teams and provide capacity for growth in the future,” said Hervé
Hoppenot, Chief Executive Officer, Incyte. “We want to extend our
thanks to Governor Carney and Mayor Purzycki for supporting this
effort; and to U.S. Senators Carper and Coons and U.S.
Representative Blunt Rochester for ensuring that Delaware is an
environment that encourages growth and innovation. We look forward
to many more years in our home state and to contributing to the
success of the downtown Wilmington community.”
“Incyte’s decision to move their headquarters to downtown
Wilmington is not only a big deal for the City – it’s a big deal
for our state,” said Governor John Carney. “Incyte is a Delaware
success story. Incyte grew out of its space at the DuPont
Experimental Station and moved hundreds of employees into a
renovated headquarters at Augustine Cut-off. Not only does this
announcement mean more, great jobs in our State – but it means that
there is more opportunity for Incyte to keep doing good in our
community and across the world. Incyte’s research makes a huge
difference in peoples’ lives. We couldn’t be prouder to call them a
Delaware-grown company and we’re excited about their next chapter.
I want to thank Incyte’s leadership for their commitment to
Delaware.”
The new building on King Street, expected to open in 2026, will
initially house 400 plus employees including the Company’s U.S.
Oncology and Dermatology teams currently located in Chadds Ford,
Pennsylvania, as well as global corporate employees currently
located at the Augustine Cut-off campus. The Company’s Research and
Development and Technical Operations teams will remain at their
current location on Augustine Cut-off in Alapocas. The North French
Street building will be used for future expansion.
“I am extremely pleased to welcome Incyte to Wilmington, a city
historically known as the home of corporate innovation, creativity
and development,” said Wilmington Mayor Mike Purzycki. “Incyte is a
company with motivated leadership that is addressing complex health
needs throughout the world. And now, that important work will be
conducted from an expanded company location in our city, and we
couldn’t be more excited. In addition to enhancing the Wilmington
business community, Incyte will provide a wonderful boost to our
local economy. I offer thanks and appreciation from our entire city
to Chief Executive Officer Hervé Hoppenot and the Incyte team and
Governor John Carney and the State team for working with the city
to make this happen.”
Today, Incyte employs more than 2,500 people across North
America, Europe and Asia, with approximately 1,200 people currently
based in Wilmington and Chadds Ford, PA.
About Incyte A global biopharmaceutical company on
a mission to Solve On., Incyte follows the science to find
solutions for patients with unmet medical needs. Through the
discovery, development and commercialization of proprietary
therapeutics, Incyte has established a portfolio of first-in-class
medicines for patients and a strong pipeline of products in
Oncology and Inflammation & Autoimmunity. Headquartered in
Wilmington, Delaware, Incyte has operations in North America,
Europe and Asia.
For additional information on Incyte, please visit Incyte.com or
follow us on social media: LinkedIn, X, Instagram, Facebook,
YouTube.
Incyte Forward-Looking Statements Except for the
historical information set forth herein, the matters set forth in
this press release, including statements regarding the Company’s
expansion in Delaware contain predictions, estimates, and other
forward-looking statements.
These forward-looking statements are based on our current
expectations and are subject to risks and uncertainties that may
cause actual results to differ materially, including unanticipated
developments in and risks related to: unanticipated delays; further
research and development and the results of clinical trials
possibly being unsuccessful or insufficient to meet applicable
regulatory standards or warrant continued development; the ability
to enroll sufficient numbers of subjects in clinical trials and the
ability to enroll subjects in accordance with planned schedules;
determinations made by the FDA and regulatory agencies outside of
the United States; the efficacy or safety of our products; the
acceptance of our products in the marketplace; market competition;
unexpected variations in the demand for our products and the
products of our collaboration partners; the effects of announced or
unexpected price regulation or limitations on reimbursement or
coverage for our products; sales, marketing, manufacturing, and
distribution requirements, including our ability to successfully
commercialize and build commercial infrastructure for newly
approved products and any additional new products that become
approved; and other risks detailed from time to time in our reports
filed with the U.S. Securities and Exchange Commission, including
our quarterly report on Form 10-Q for the quarter ended March 31,
2023. We disclaim any intent or obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521531442/en/
Media media@incyte.com
Investors ir@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From May 2024 to Jun 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2023 to Jun 2024